{
    "root": "361f79e5-0981-c4de-e063-6394a90a39ac",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Sodium Polystyrene Sulfonate",
    "value": "20250527",
    "ingredients": [
        {
            "name": "SODIUM POLYSTYRENE SULFONATE",
            "code": "1699G8679Z"
        }
    ],
    "indications": "Sodium Polystyrene Sulfonate Powder, for Suspension is indicated for the treatment of hyperkalemia.\n                  \n                     Limitation of Use:\n                  \n                  Sodium Polystyrene Sulfonate Powder, for Suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action\n \n  \n                        [see Clinical Pharmacology (12.2)]\n                     .",
    "contraindications": "Oral : The average total daily adult dose of Sodium Polystyrene Sulfonate Powder, for Suspension is 15 g to 60 g, administered as a 15-g dose (four level teaspoons), one to four times daily ( 2.1 ). Rectal : The average adult dose is 30 g to 50 g every six hours ( 2.1 ).",
    "warningsAndPrecautions": "Sodium Polystyrene Sulfonate Powder, for Suspension is available as follows:\n                  ndc 17856-0024-01  SODIUM POLYSTYRENE SULFONATE PWD 15 GM CUP 50 ct UD\n                  ndc 17856-0024-02  SODIUM POLYSTYRENE SULFONATE PWD 30 GM CUP 50 ct UD\n                  \n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].",
    "adverseReactions": "Sodium Polystyrene Sulfonate Powder, for Suspension is contraindicated in patients with the following conditions:\n                  •Hypersensitivity to polystyrene sulfonate resins \n    •Obstructive bowel disease \n    •Neonates with reduced gut motility"
}